Exscientia wants to bring its AI/ML approach into the world of biologics. It's starting with antibodies
Exscientia is looking at breaking out of small molecule R&D.
The UK biotech announced Thursday that it is expanding its R&D efforts into biologics, more specifically antibodies, looking to implement precision engineering and utilize in silico screening. And in order to put the expansion into place, Exscientia also announced that it will be adding new building space to its headquarters to house the new laboratory.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.